HBK Sorce Advisory LLC Takes Position in Kenvue Inc. $KVUE

HBK Sorce Advisory LLC purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 87,459 shares of the company’s stock, valued at approximately $1,720,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. grew its holdings in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new position in shares of Kenvue during the 4th quarter worth $26,000. MV Capital Management Inc. purchased a new position in shares of Kenvue during the 4th quarter worth $28,000. CoreCap Advisors LLC boosted its position in shares of Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after acquiring an additional 591 shares during the last quarter. Finally, Reflection Asset Management acquired a new position in shares of Kenvue during the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the topic of several analyst reports. Barclays lifted their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. UBS Group reduced their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $19.27.

Kenvue Stock Performance

NYSE KVUE opened at $19.20 on Monday. The company has a market cap of $36.87 billion, a P/E ratio of 22.06, a P/E/G ratio of 1.37 and a beta of 0.47. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The stock has a 50-day moving average of $18.95 and a two-hundred day moving average of $18.14. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $21.84.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $0.29 earnings per share. As a group, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.